GlassScriptPhysician profile
Deborah S Goddard
NPI 1255463733
$1,609.98
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $291 · 2021: $115 · 2022: $27.68 · 2024: $13.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $413.44 | 2019-2022 | |
| Abbvie INC. | $183.20 | 2019-2020 | |
| Janssen Biotech, INC. | $158.79 | 2019 | |
| Aclaris Therapeutics, INC. | $131.53 | 2019 | |
| Lilly USA, LLC | $103.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $103.19 | 2019-2020 | |
| Genzyme Corporation | $100.84 | 2019-2020 | |
| Amgen INC. | $56.87 | 2020 | |
| Dermira, INC. | $50.47 | 2019 | |
| Celgene Corporation | $46.70 | 2019 | |
| Pfizer INC. | $46.46 | 2019 | |
| Galderma Laboratories, L.P. | $43.04 | 2019-2024 | |
| Allergan, INC. | $35.54 | 2020 | |
| Mayne Pharma Commercial LLC | $35.06 | 2019 | |
| Mission Pharmacal Company | $29.28 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $24.04 | 2020 | |
| Almirall LLC | $19.06 | 2019 | |
| Ucb, INC. | $15.06 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Goddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.